Novamind is building the infrastructure required for a regulated psychedelics industry
Why psychedelics?
— Stanislav Grof, MD
We are dedicated to advancing psychedelic research and catalyzing personal wellness.
Read about usFebruary 23, 2021
Novamind to Present at Benzinga Conference
February 22, 2021
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF
February 19, 2021
Novamind Announces Symbol Change on OTC Market To “NVMDF”
February 11, 2021
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial